Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 1
1985 1
1986 1
2016 1
2017 2
2019 2
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Among authors: tokutake e. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Konishi M, et al. Among authors: tokutake e. Int J Cardiol. 2022 Feb 15;349:127-133. doi: 10.1016/j.ijcard.2021.11.076. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34864084 Clinical Trial.
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Kojima S, et al. Among authors: tokutake e. Eur Heart J. 2019 Jun 7;40(22):1778-1786. doi: 10.1093/eurheartj/ehz119. Eur Heart J. 2019. PMID: 30844048 Free PMC article. Clinical Trial.
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: tokutake e. Rheumatology (Oxford). 2022 May 30;61(6):2346-2359. doi: 10.1093/rheumatology/keab739. Rheumatology (Oxford). 2022. PMID: 34605897 Clinical Trial.
Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease.
Arao K, Yasu T, Endo Y, Funazaki T, Ota Y, Shimada K, Tokutake E, Naito N, Takase B, Wake M, Ikeda N, Horie Y, Sugimura H, Momomura SI, Kawakami M; Investigators of the Anti-Arteriosclerosis and Lipid Lowering with Pitavastatin Evaluation Study in Nippon (ALPEN). Arao K, et al. Among authors: tokutake e. Heart Vessels. 2017 Oct;32(10):1186-1194. doi: 10.1007/s00380-017-0988-1. Epub 2017 May 2. Heart Vessels. 2017. PMID: 28466409 Free PMC article.
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) investigators. Kojima S, et al. Among authors: tokutake e. Cardiovasc Drugs Ther. 2023 Oct;37(5):965-974. doi: 10.1007/s10557-022-07347-7. Epub 2022 Jun 1. Cardiovasc Drugs Ther. 2023. PMID: 35648242 Clinical Trial.
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: tokutake e. J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20. J Cardiol. 2017. PMID: 27005768 Free article. Clinical Trial.
17 results